AVASTIN (bevacizumab), monoclonal antibody - CERVICAL CANCER

• AVASTIN has Marketing Authorisation in adults with persistent, recurrent or metastatic cervical cancer, in combination with paclitaxel and cisplatin (or in combination with paclitaxel and topotecan in those who cannot receive platinum-based treatment).
• The addition of bevacizumab to chemotherapy has demonstrated a moderate effect on overall survival, but with reservations about the strength of the results and at the cost of accrued toxicity, especially recto-vaginal fistulas, compared to chemotherapy by carboplatin and paclitaxel.

-